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ABSTRACT
Globally, lung cancer is the leading cause of cancer-
related mortality. Current chemotherapy combinations
for the first-line treatment of advanced disease (stage
IIIB with malignant pleural effusion/stage IV) and che-
moradiotherapy regimens for the treatment of unre-
sectable locally advanced disease (stage IIIA and IIIB
without malignant pleural effusion) appear to have
reached an efficacy plateau. The addition of new com-
pounds including targeted agents to standard first-line
cytotoxicdoublets,administeredconcurrentlyand/oras
maintenance therapy in patients who have not experi-
enced disease progression after such treatment, has
been shown to improve efficacy beyond this plateau in
patients with advanced disease. However, to date, such
approacheshavebeenlesssuccessfulinthetreatmentof
patients with unresectable locally advanced stage III
disease. The purpose of this review is to summarize the
data from recent randomized phase III studies involving
agentsadministeredasmaintenanceorconsolidationther-
apyinthetreatmentofunresectablestageIII/IVnon-small
celllungcancer(NSCLC).Apossiblealternativeapproach
to the use of cytotoxic or molecularly targeted agents in
this setting is the administration of therapeutic anticancer
vaccines, which are designed to stimulate a host immuno-
logical response against the tumor. Current data in rela-
tion to the potential of vaccine therapy for NSCLC are
therefore also reviewed, with a particular focus on belag-
enpumatucel-L and L-BLP25 vaccines, which are cur-
rently undergoing phase III evaluation as maintenance
therapies in patients with unresectable stage III/IV
NSCLC who have tumor control following first-line ther-
apy. The Oncologist 2010;15:1034–1042
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Globally,lungcancerremainsthemostcommoncancerand
the leading cause of cancer-related mortality [1]. In Europe
alone, it was estimated that there were 334,800 deaths at-
tributable to the disease in 2006 [2] and the European mean
age-adjusted 5-year survival rate for patients diagnosed be-
tween 2000 and 2002 was a disappointing 10.9% [3]. Ap-
proximately 80% of tumors are of the non-small cell lung
cancer(NSCLC)subtype[4](predominantlysquamouscell
carcinomas, adenocarcinomas, and large cell carcinomas).
Clinicopathological stage at diagnosis assessed according
to the International System for Staging Lung Cancer based
on tumor node metastasis status remains a key predictor of
survival time [5].
Patients with early-stage NSCLC may be cured by sur-
gical resection, with adjuvant chemotherapy significantly
improving relapse-free and overall survival in this setting
compared with surgery alone [6]. However, largely as a
consequence of the lack of symptoms during the early
stages and the absence of a proven screening technology,
most patients with NSCLC currently present with unresect-
ablediseaseeitherlocallyadvanced(stageIII)ormetastatic
to distant sites (stage IV) [7, 8].
Standardfirst-linetreatmentforpatientsofgoodperfor-
mance status with advanced NSCLC (stage IIIB with ma-
lignant pleural effusion or stage IV on the previous staging
system,nowbothincludedasstageIVintherevisedsystem
[8]) remains palliative chemotherapy. This generally com-
prises one of several equally effective cytotoxic doublets,
which include a platinum analogue combined with either
vinorelbine, gemcitabine, a taxane, or for patients with
nonsquamous disease, pemetrexed [9–11]. The addition of
a targeted agent (either cetuximab or bevacizumab) to such
regimens has been shown to significantly improve overall
survival for certain combinations compared with the same
chemotherapy alone [12, 13] but not for others [14, 15].
StandardtreatmentforpatientswithstageIIIdisease,which
is not associated with malignant pleural effusion but which
is unresectable, comprises chemotherapy combined with
thoracic radiation (chemoradiotherapy) [16–18]. Whether
the efficacy of such approaches can be improved by the use
of maintenance therapy has recently been investigated in a
seriesofstudies.Thepurposeofthisreviewistosummarize
phase III study data relating to maintenance and consolida-
tion therapy for unresectable stage III/IV NSCLC.
MAINTENANCE AND CONSOLIDATION THERAPIES
FOR UNRESECTABLE NSCLC
Maintenance therapy has been defined as treatment that is
administered after the end of a defined number of chemo-
therapy cycles, in patients whose tumor has been con-
trolled, and which continues typically until the occurrence
of unacceptable toxicity or disease progression. In contrast,
when postchemotherapy systemic treatment is continued
instead for a fixed period of time/number of cycles, it is
termed consolidation therapy. A further distinction may be
drawninrelationtowhethertheagentsusedinmaintenance
or consolidation therapy have been administered in the
first-line combination (or have an essentially similar mode
of action to one of those agents) or whether they have a dif-
ferent mode of action. In the latter case, such therapy may
be termed early second-line treatment [19]. However,
while these different classifications may help to define
the nature of particular studies, perhaps the most impor-
tant point to make is that agents used in long-term main-
tenancetherapywillprobablyneedtobethoseassociated
with minimal toxicity, if quality of life for the patient is
not to be impacted upon negatively. For consolidation
therapy, administered over a defined and typically
shorterperiodoftime,itmaybethattherisk/benefitratio
will permit the use of agents that are associated with
higher levels of toxicity.
ADVANCED NSCLC
As a substantial fraction of patients with advanced NSCLC
will not receive second-line treatments, commonly because
of rapid disease progression and a corresponding drop in
performance status, attention has turned increasingly to the
roleofconsolidationandmaintenancetherapyinimproving
overall survival times in this setting [20]. Targeted thera-
pies are also increasingly becoming the focus of clinical re-
search in the treatment of advanced NSCLC [21].
Randomized studies have demonstrated that the addition of
targeted agents to standard first-line regimens and their
continued administration as maintenance therapies or the
use of particular agents as maintenance therapy following
standard first-line treatment are both effective strategies in
relation to improving overall survival.
CYTOTOXIC AGENTS AS CONSOLIDATION OR
MAINTENANCE THERAPIES
Theoptimumtimingofsecond-linetherapywasexploredin
a phase III randomized study in which patients with stage
IIIB with pleural effusion or stage IV NSCLC received a
plannedfourcyclesofgemcitabinepluscarboplatinasfirst-
line treatment [22]. The 309 on-study patients who did not
have disease progression at this point were randomized to
receive immediate docetaxel consolidation therapy (six cy-
cles maximum) or best supportive care (BSC) until disease
progression, at which time and if fit enough, they received
the same docetaxel regimen (delayed docetaxel). Although
toxicity profiles were broadly comparable and quality of
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mediate versus delayed docetaxel groups, progression-free
survival (PFS) was significantly longer for patients in the
immediate docetaxel group (median 5.7 versus 2.7 months,
p  .0001). There was also a trend for superior survival for
patients in this arm (median 12.3 versus 9.7 months in the
delayed docetaxel arm, p  .085).
Maintenance therapy with a cytotoxic agent was also
shown to be an effective approach in the randomized, dou-
ble-blind phase III JMEN study comparing the antifolate
compound pemetrexed plus BSC with placebo plus BSC in
663 patients with advanced (stage IIIB/IV) NSCLC who
had not progressed on four cycles of platinum-based che-
motherapy which did not include pemetrexed [23]. The ad-
ministration of pemetrexed resulted in improved overall
survival (median 13.4 versus 10.6 months, hazard ratio
[HR] 0.79, p  .012), response rate, and PFS in patients
who had responded to the initial chemotherapy. A clear in-
teraction between treatment efficacy in relation to overall
survival time and histology was apparent (p  .033) with
benefit seen predominantly in patients with nonsquamous
histology (median 15.5 versus 10.3 months, respectively,
HR, 0.70, p  .002).
Although both of these studies confirmed that the ad-
ministration of consolidation or maintenance therapy with
an agent not used in the first-line treatment regimen im-
proved clinical outcome, neither trial was informative as to
whether the benefit was primarily as a consequence of in-
creased anticancer activity of the three-drug sequential reg-
imens or whether it was essentially due to more patients
beingexposedtothreetreatmentagentsasaconsequence
of early second-line therapy. Indeed, in the study evalu-
ating immediate versus delayed docetaxel, median sur-
vival for patients who actually received docetaxel in the
delayedarm(63%)wasthesameat12.5monthsasthatof
the safety population of patients in the immediate do-
cetaxel arm, suggesting that the second explanation may
have been more likely in this particular case. However,
regardless of the underlying mechanism, the key point is
that these particular treatment strategies appeared to im-
prove clinical outcome in this setting, with pemetrexed
maintenance therapy significantly improving overall
survival compared with placebo.
TARGETED AGENTS AS MAINTENANCE THERAPIES
Aseriesofrandomizedstudieshaveclinicallyvalidatedthe
epidermal growth factor receptor (EGFR) as an effective
molecular target in relation to the treatment of advanced
NSCLC. In the first-line setting, the phase III FLEX (First-
LineErbituxinLungCancer)studyincluded1125random-
izedpatientswithEGFR-expressingstageIIIBdiseasewith
malignantpleuraleffusionorstageIVdiseasewhowereun-
selected according to tumor histology. The study demon-
strated that the addition of the EGFR-specific monoclonal
antibody cetuximab to cisplatin and vinorelbine followed
by cetuximab maintenance therapy significantly improved
survival when compared with cisplatin and vinorelbine
alone(median11.3versus10.1months,HR0.87,p.044)
[13, 24]. A second study, BMS099 (Bristol-Myers Squibb
099), exploring taxane plus carboplatin with or without
cetuximab as first-line treatment for advanced NSCLC,
showed a similar overall survival benefit for the addition of
cetuximab, (administered concurrently with chemotherapy
andasamaintenancetreatmentuntildiseaseprogression)to
astandardcytotoxicdoublet.However,giventhenumberof
patients in the study, this difference was not statistically
significant (median 9.7 versus 8.4 months, HR 0.89, p 
.169) [14].
The vascular endothelial growth factor has also been
shown to be an effective therapeutic target in this setting in
the Eastern Cooperative Oncology Group (ECOG) 4599
study, which demonstrated that the addition of bevaci-
zumab to paclitaxel plus carboplatin followed by bevaci-
zumab maintenance therapy significantly improved overall
survival compared with paclitaxel plus carboplatin alone in
the first-line treatment of advanced NSCLC (median 12.3
versus 10.3 months, HR 0.79, p  .003) [12]. Another
study, AVAiL (Avastin in Lung Study), exploring cisplatin
plus gemcitabine with either bevacizumab, at 7.5 or 15 mg/
kg, or placebo (each administered concurrently with che-
motherapy and as a maintenance treatment until disease
progression), demonstrated a significant improvement in
PFS in the primary analysis for patients with advanced
NSCLC receiving chemotherapy plus bevacizumab at both
dose levels compared with chemotherapy plus placebo
[25]. However, an overall survival benefit was not demon-
strated for either the 7.5 or 15 mg/kg bevacizumab regi-
mens (median 13.6 and 13.4 versus 13.1 months, HR 0.93
and HR 1.03, p  .420 and p  .761, respectively) [15].
Thedesignofthesefourrandomizedstudiesdoesnotal-
low for conclusions to be drawn as to whether the clinical
benefit associated with the addition of the targeted agent to
standard first-line chemotherapy was conferred during the
chemotherapy,maintenance,orindeedbothphasesoftreat-
ment. To specifically demonstrate that a particular agent is
effective as maintenance therapy, alternative study designs
are required.
The double-blind randomized phase III Sequential
Tarceva in Unresectable NSCLC (SATURN) study of
maintenance erlotinib (an EGFR tyrosine kinase inhibitor
[TKI]) versus placebo in patients with advanced, recurrent,
or metastatic disease who had not progressed following
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onstrated that erlotinib maintenance therapy significantly
reduced the risk of disease progression (median PFS 12.3
versus 11.1 weeks, HR 0.71, p  .0001), improved disease
control, and improved overall survival (HR 0.81, p  .009)
in this setting compared with placebo [26, 27]. Another
phase III study also showed promising results for a second
EGFR TKI, gefitinib, administered as maintenance therapy
[28]. In the West Japan Thoracic Oncology Group (WJ-
TOG)0203 study, 604 chemotherapy-naive patients with
advanced (stage IIIB/IV) NSCLC were randomized to re-
ceive three cycles of platinum doublet chemotherapy fol-
lowed by gefitinib daily, or six cycles of platinum doublet
chemotherapy alone. PFS was significantly longer in the
gefitinib maintenance arm (median 4.6 versus 4.3 months,
HR 0.68, p  .001) and overall survival significantly im-
provedinpatientsinthisarmwithadenocarcinoma(median
15.4 versus 14.3 months, HR 0.79, p  .03). Gefitinib
maintenancetherapyfailedtosignificantlyimproveoverall
survival for the full population compared with platinum
doublet chemotherapy alone [28].
The potential of maintenance therapy to improve out-
comesinthetreatmentofadvanceddiseasehasbeenfurther
demonstrated in the randomized double-blind phase IIIb
ATLAS study. Seven hundred sixty-eight patients with lo-
cally advanced, recurrent, or metastatic (stage IIIB/IV)
nonsquamous NSCLC who had received four cycles of
first-line chemotherapy plus bevacizumab and who had not
experienced disease progression or unacceptable toxicity
were randomized to receive bevacizumab plus erlotinib or
bevacizumab plus placebo as maintenance therapy. The
trialwashaltedatthesecondplannedinterimefficacyanal-
ysis after a significant improvement in PFS (median 4.8
versus3.7months,HR0.72,p.001)wasdemonstratedin
the bevacizumab plus erlotinib arm [29].
UNRESECTABLE STAGE III NSCLC
Patients with unresectable locally advanced stage III dis-
ease(IIIAandIIIBwithoutmalignantpleuraleffusion)also
comprise an important target population in clinical re-
search. Although there is a better chance of a positive out-
come in such patients given that overt disease is limited to
the thoracic cavity, it has become clear in recent years that
a plateau has been reached in terms of what is achievable
with chemotherapy and radiotherapy in this setting. Sur-
vival figures currently observed in selected patients with
stage III NSCLC treated with concurrent chemoradiother-
apy are in the order of a median survival time of 17 months
and a 3-year survival rate of 25% [30]. Although these
clearly represent an improvement in outlook from only a
few years ago, novel strategies which improve survival
while not increasing toxicity to unacceptable levels are ur-
gently needed. To this end, attention has turned to whether
the incorporation of consolidation or maintenance therapy
into treatment regimens for stage III disease might improve
clinical outcome. Although current data are somewhat lim-
ited, several randomized studies have been carried out in
this setting.
SubsequenttotheSouthwestOncologyGroup(SWOG)
S9504 phase II study, which demonstrated the feasibility
and tolerability of docetaxel as consolidation therapy fol-
lowing concurrent chemoradiotherapy in patients with
stage IIIB disease [31], the potential of this approach was
further investigated in a phase III study conducted by the
Hoosier Oncology Group and US Oncology [32]. Eligible
patients with unresectable stage IIIA or IIIB NSCLC ini-
tially received 50 mg/m
2 cisplatin days 1 and 8 plus 50
mg/m
2 etoposide days 1–5, every 28 days for two cycles,
administered concurrently with chest radiation (33 frac-
tions to 59.40 Gy). One hundred forty-seven patients who
did not experience progression were subsequently ran-
domly assigned to 75 mg/m
2 docetaxel every 21 days for
three cycles or observation. During the 9 weeks following
randomization, more patients were hospitalized in the do-
cetaxel compared with the observation arm (29% versus
8%).Incidenceratesofpneumonitisandinfectionwerealso
significantly higher in the docetaxel arm and there were
four treatment-related deaths. On the basis of evidence of
futility following an interim analysis of overall survival
time, the data and safety monitoring board recommended
theearlyclosureofthisstudy.Medianoverallsurvivaltime
was 21.2 months in the docetaxel arm compared with 23.2
months in the observation arm (p  .883). Consolidation
therapy with docetaxel therefore appeared to have in-
creased toxicity without improving overall survival in this
setting.
Another randomized phase III study, SWOG S0023, in-
vestigated gefitinib as maintenance therapy following che-
moradiotherapy and docetaxel consolidation therapy [33].
UntreatedpatientswithstageIIIdiseasereceived50mg/m
2
cisplatin days 1 and 8 plus 50 mg/m
2 etoposide days 1–5,
every 28 days, for two cycles with concurrent thoracic ra-
diation (total dose 61 Gy). Four to 8 weeks after the com-
pletion of radiotherapy, 429 eligible patients without
progressive disease were reregistered to receive up to three
cyclesof75mg/m
2docetaxel,day1every21days.Threeto
6 weeks after the last dose of docetaxel, 243 eligible pa-
tients who had not experienced disease progression were
randomlyassignedtoreceivegefitinibmaintenancetherapy
orplacebofor5yearsoruntiltheoccurrenceofdiseasepro-
gression or unacceptable toxicity. The study was subse-
quently closed early after an unplanned interim analysis
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survivalinthegefitinibarmatthep.0015level.Atame-
dian follow-up time of 27 months, the median overall sur-
vival time from the date of random assignment was 23
monthsinthegefitinibarmcomparedwith35monthsinthe
placebo arm (HR 0.63, p  .013). The reason for the infe-
rior overall survival in the gefitinib arm was not clear and
did not appear to be the result of imbalance between the
treatment groups in relation to baseline characteristics or
toxicity. Indeed, the toxic death rate was only 2% for pa-
tients receiving gefitinib compared with 0% for those re-
ceiving placebo.
These two phase III studies have therefore proved to be
disappointing in that neither docetaxel consolidation ther-
apy or gefitinib maintenance following docetaxel consoli-
dation therapy appear to have improved overall survival in
patients with stage III NSCLC who had received chemora-
diotherapy.Althoughotherongoingrandomizedstudiesare
exploringtheroleofvarioustargetedagentsasmaintenance
therapy in the treatment of advanced stage IIIB/IV disease,
including investigations of sunitinib and ZD6474 (vandet-
anib) administered following disease control after plati-
num-based first-line treatment, further studies are
investigating the potential of therapeutic vaccines as main-
tenance treatments. The use of therapeutic vaccines in this
setting represents a novel approach and a number of phase
III trials are currently under way to assess the potential of
this strategy.
IMMUNOTHERAPY FOR UNRESECTABLE
STAGE III/IV NSCLC
Although tumor-specific immune responses have been de-
tected in patients, for a tumor to have developed to an ad-
vanced stage, pre-existing immunity must have been
insufficient for tumor eradication. Possible reasons for this
poor immunological response include acquired or innate
host tolerance to tumor-associated antigens, tumor devel-
opment in an immunoprivileged site, or the expression of
tumor-associated proteins that have suppressed the activity
of cytotoxic T lymphocytes [34]. Therapeutic anticancer
vaccines are intended to provoke or augment an adaptive
immune response to the patient’s tumor cells. There are
therefore two challenges associated with developing a suc-
cessful anticancer vaccine therapy: the identification of a
specific antigenic stimulus that will be recognized as im-
munogenic by the patient’s immune system [35] and the
creation of an efficient delivery system to stimulate a suffi-
ciently large immune response to the antigen and thereby
yield a clinically relevant result. Two vaccines that exem-
plify different approaches are currently being investigated
in phase III studies as maintenance treatments following
chemotherapy or chemoradiotherapy for stage III or IV
NSCLC: belagenpumatucel-L in patients with stage III/IV
diseaseandtheliposomalvaccineL-BLP25inpatientswith
unresectable stage III disease. These vaccines are designed
to present different antigenic stimuli to the host immune
system.
Belagenpumatucel-Lisanonviralvaccinederivedfrom
extracts of four allogeneic NSCLC cell lines, which have
been transfected with a plasmid encoding a transforming
growth factor (TGF)-2 antisense transgene. The antisense
construct was designed to suppress the expression of
TGF-2 within the tumor cells comprising the vaccine and
therebyhopefullyincreasetheimmunogenicityofthiscom-
plex preparation. A three-arm phase II study evaluated the
safety and efficacy of intradermal immunization with three
differentdoselevelsofthisvaccinein75patientswithstage
II,III,orIVNSCLC[36].Belagenpumatucel-L,whichwas
used as an upfront rather than maintenance therapy in this
study,waswelltoleratedandadose-relatedsurvivalbenefit
was demonstrated for patients receiving the higher versus
lower doses of the vaccine (p  .007). A response rate of
15% was reported for 61 patients with stage IIIB/IV dis-
ease. In a subsequent analysis, patients with both a cellular
and humoral immune response to this vaccine had im-
proved overall survival compared with those classified as
immune response negative (median 32.5 versus 11.6
months, p  .011) [37]. An ongoing randomized phase III
vaccine study (STOP: Survival, Tumor-free Survival,
Overall Survival, and Progression-Free Survival) is com-
paring the overall survival of patients with stage IIIA (T3,
N2 only), IIIB, or IV NSCLC receiving belagenpumatu-
cel-L or placebo. Patients with stable disease or an objec-
tive response after first-line platinum-based chemotherapy
with or without concomitant radiotherapy will be random-
izedtoreceiveintradermalbelagenpumatucel-Lorplacebo.
Adifferentbasicapproachhasbeenemployedinthede-
velopment of the L-BLP25 vaccine. Rather than using an
extract of whole tumor cells as a complex antigenic stimu-
lus,theL-BLP25vaccineisbasedonaspecificprotein,mu-
cin1(MUC1),whichiswidelyexpressedinnormaltissues,
but which is post-translationally modified in tumor cells to
expose a novel antigenic site [38]. MUC1, encoded by the
MUC1 gene on human chromosome 1q22, is a heavily gly-
cosylatedtransmembraneproteinthatisfoundontheapical
surface of a wide range of normal epithelial cells from dif-
ferent tissues. In tumor cells, the extracellular domain of
MUC1 may be abnormally glycosylated, exposing to the
host immune system a highly immunogenic core peptide of
the protein consisting of a 20-amino acid tandem repeating
sequence [39]. L-BLP25 is a liposome-based vaccine con-
sisting of a synthetic 25-amino acid lipopeptide derived
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nonspecific adjuvant monophosphoryl lipid A and three
different lipids [40]. The use of a liposome-based delivery
system was intended to facilitate uptake of the antigenic
peptide by antigen-presenting cells, and preclinical studies
found that L-BLP25 was indeed capable of inducing a cel-
lular immune response in mice [41].
MUC1isstronglyexpressedinnormallungtissueandis
commonly expressed in tumors and non-neoplastic lesions
(hyperplasia, metaplasia) of the bronchial tissue [42, 43].
The pattern and level of MUC1 expression in tumors has
also been associated with poor prognosis in patients with
NSCLC[44–47].Furthermore,the1-yearsurvivalratewas
higher in patients with NSCLC who had high compared
with low levels of natural MUC1 antibodies [48]. Such ob-
servations provided a biological rationale, suggesting that
inducing an anticancer immune response to MUC1 using a
vaccination strategy might be an effective approach in the
treatment of NSCLC. L-BLP25 is the first investigational
lung cancer vaccine to enter phase III clinical testing in the
treatmentofunresectablestageIIINSCLC;itsstructureand
proposed mode of action are illustrated in Figure 1.
CLINICAL TRIALS WITH L-BLP25
A phase I study which recruited 17 patients with stage
IIIB/IV NSCLC demonstrated that L-BLP25 could be
safely administered in this setting [49]. Two subsequent
phase II studies established an effective dose and schedule
[50] and facilitated the design of a randomized phase IIB
trial to evaluate the efficacy and safety of L-BLP25 in pa-
tients with stage IIIB/IV NSCLC whose disease had re-
spondedtoorwasstableafterfirst-linetherapy[51].Atotal
of 171 patients were enrolled and randomized to receive L-
BLP25 with BSC or BSC alone. Patients in the L-BLP25
arm received low-dose cyclophosphamide 3 days prior to
treatment with L-BLP25 at 1000 g/wk for 8 weeks. The
primary endpoint of the study was overall survival. After a
median follow-up time of 52 months, patients receiving L-
BLP25 had a median overall survival time of 17.2 months
compared with 13.0 months in the control arm, although
this difference did not reach statistical significance (HR
0.75, adjusted p  .085). A stronger trend toward longer
overall survival time in the L-BLP-25 compared with the
control arm was observed in the subgroup of 65 stage IIIB
patientswithlocoregionaldisease(median30.6versus13.3
months, HR 0.55; Fig. 2), whereas no benefit from the vac-
cine was apparent for patients with stage IIIB with malig-
nant pleural effusion/stage IV disease (median 15.1 versus
12.9 months, respectively, HR 0.91) [51; 52, and updated
data presented at meeting]. This perhaps indicates that pa-
tientswithalowertumorburdenmayhaveagreaterchance
of deriving a significant clinical benefit from this particular
immunotherapy. It is conceivable that vaccines based on
differentantigenicstimulimayworkbetterinparticularset-
tings,accordingtothetypicalgeneexpressionpatternofthe
tumor cells and characteristic host immune capability at a
given stage of disease. In this respect, the broader antigenic
profile of complex cell-based vaccines such as belagenpu-
Figure 1. Proposed mode of action of L-BLP25.
Abbreviations:APC,antigen-presentingcell;CTL,cytotoxicTlymphocyte;HLA,humanleukocyteantigen;IFN,interferon
gamma; MPL, monophosphoryl lipid A; MUC1, mucin 1; Th1, T-helper lymphocyte; TCR, T-cell receptor.
1039 Thatcher, Heighway
www.TheOncologist.commatucel-Lmaybemoresuitedtothetreatmentofadvanced
stage metastatic disease.
No significant toxicity was reported in the L-BLP25
arm of this study, with grade 1 flu-like symptoms and ad-
verse events related to cyclophosphamide being the most
frequent side effects. Quality of life (QoL) analysis re-
vealed a clear advantage for the L-BLP25 over the BSC
arm, with more patients in the vaccine arm demonstrating a
clinically meaningful improvement or no change in QoL
and more patients in the BSC arm demonstrating a clini-
callymeaningfulworseninginthetrialoutcomeindex[51].
A safety analysis of 16 patients from this study who re-
ceived L-BLP25 for between 2.0 and 7.7 years concluded
that long-term use of the vaccine was without identifiable
safetyissuesandthattherewasnoevidenceofautoimmune
reactions with prolonged use [53].
The results of this phase II study therefore showed that
maintenance therapy with L-BLP25 in patients with unre-
sectable locoregional stage IIIB NSCLC is at least feasible
and may have the potential to prolong survival in this pa-
tient group. To investigate this hypothesis further, the effi-
cacy and safety of L-BLP25 is now being evaluated in a
large phase III study [40]. The multicenter, randomized,
double-blind,placebo-controlledStimulatingTargetedAn-
tigenic Responses To NSCLC (START) trial will enroll
morethan1,300patientswithstageIIINSCLCwhohave
previously completed chemoradiotherapy treatment and
whohavestablediseaseoranobjectiveclinicalresponse.
Accrual into START is ongoing; if L-BLP25 is found to
be effective in this trial, then vaccination could replace
watchful waiting as the standard of care following che-
moradiotherapy treatment for patients with stage III
NSCLC.
CONCLUSIONS
Despite continuing improvements in chemoradiotherapy
regimens and the recent clinical validation of particular
agents as maintenance treatments in advanced disease,
there remains an unmet need for new therapies with clin-
ically proven value in the treatment of unresectable stage
III NSCLC. Initial randomized trials of maintenance
therapies in this setting have been disappointing.
Whetherthenovelapproachofadministeringtherapeutic
vaccines to patients with tumor control after first-line
chemotherapy or chemoradiotherapy improves survival
in patients with stage III and IV disease is also currently
being explored in phase III studies. As these studies ma-
ture, it will be possible to assess whether the use of anti-
cancer vaccines may be an effective strategy in the
treatment of NSCLC.
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Figure 2. Kaplan-Meier overall survival analysis for stage IIIB locoregional NSCLC patients receiving L-BLP25 [52].
Abbreviations: BSC, best supportive care; NA, not available; NS, not significant.
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